Description du projet DEENESFRITPL Musicothérapie pour les acouphènes Les acouphènes ou bourdonnements d’oreilles désignent la sensation d’entendre des sons en l’absence de tout bruit extérieur réel. La gravité des acouphènes est difficile à déterminer et, selon leur cause, il existe différentes options de traitement. Cependant, il n’existe pas encore de remède permanent et les personnes qui en souffrent sont souvent incapables de travailler ou de socialiser, ce qui implique des conséquences socio-économiques évidentes. Le projet TinniMizer, financé par l’UE, a mis au point un traitement de musicothérapie rentable et facile à utiliser. Le système devrait atténuer l’impact négatif des acouphènes après seulement trois mois de traitement, contre un an et demi pour les autres systèmes de thérapie sonore. Afficher les objectifs du projet Masquer les objectifs du projet Objectif Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The medical doctors (ENT specialists), audiologists, and electronics-biomedical engineers in Genmel Technology have developed a new, patient-specific, state-of-the-art, and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure the tinnitus with an easy-to-use and cost-effective therapeutic system. Preliminary results obtained from about 20 patients at three clinics (Tinnitus Treatment Centers) indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. Through this project, Genmel will further develop this therapy to result in over 95% reduction in tinnitus. In other sound therapy systems, the duration of therapy is 1.5 years. Our goal is to reduce this period to a much shorter period (up to 3 months). Genmel offers R&D solutions, productions, and consulting services especially in the field of Biomedical, Electronics, Medicine and Energy. Academicians, engineers and technicians are working in GENMEL. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. Through this project, Genmel aims to achieve a total turnover of >€14.5 million by the 5th year of TinniMizer commercialization. Champ scientifique medical and health sciencesclinical medicineotorhinolaryngology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-1 Régime de financement SME-1 - SME instrument phase 1 Coordinateur GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE TICARET LIMITED SIRKETI Contribution nette de l'UE € 50 000,00 Adresse CIFTEHAVUZLAR MAH. ESKI LONDRA ASFALTI CAD. KULUCK ERC1 BLOK 151/1E/105 34220 ISTANBUL Turquie Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région İstanbul İstanbul İstanbul Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
